CG Oncology, Inc.
CGON · XNASCIK 1991792fmd_1EG9KKN95DQHKEMV9H8WAK3KW4Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2023 to Sep 30, 2026, 15 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total revenues | 0 | 1 | 4 |
| Research and development | 46 | 82 | 117 |
| Total operating expenses | 56 | 116 | – |
| Operating income | (55) | (115) | (191) |
| Interest and investment income | 7 | 27 | 30 |
| Other non-operating income (expense) | 7 | 27 | 30 |
| Income tax expense | 0 | 0 | (0) |
| Net income | (49) | (88) | (161) |
| Net income to common shareholders | (68) | (88) | (161) |